File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: A 10-year follow-up study

TitleOral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: A 10-year follow-up study
Authors
Issue Date2011
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
Blood, 2011, v. 118 n. 25, p. 6535-6543 How to Cite?
AbstractSeventy-six patients with acute promyelocytic leukemia (APL) in first complete remission after induction and consolidation by daunorubicin and cytosine arabinoside received oral arsenic trioxide (As 2O 3)-based maintenance. Three regimens were used: oral As 2O 3 (10 mg/day, regimen A, n ∇ 20), oral As 2O 3 plus all-trans retinoic acid (ATRA, 45 mg/m 2 per day, regimen AA, n ∇ 19), and oral As 2O 3plus ATRA plus ascorbic acid (1000 mg/day, regimen AAA, n ∇ 37), each given for 2 weeks every 2 months for 2 years. Patients receiving A, AA, and AAA maintenance did not differ significantly in clinicopathologic features and risk factors. Headache, dyspepsia, reversible liver function derangement, and herpes zoster reactivation were adverse effects observed during maintenance. QTc prolongation and arrhythmias were not encountered. At a median follow-up of 24 months (range, 1-115 months), there were 8 relapses. The 3-year leukemia-free-survival, event-free-survival, and overall-survival were 87.7%, 83.7%, and 90.6%, respectively. Adverse prognostic factors included male gender for leukemia-free-survival, and unrelated cancers for overall survival. Age, presentation WBC count and platelet count, and the type of oral As 2O 3 maintenance regimens had no impact on survivals. Prolonged oral As 2O 3 maintenance was feasible and safe and resulted in favorable outcomes when used with a simple induction and consolidation regimen compared with other protocols composed of multiple chemotherapeutic agents. © 2011 by The American Society of Hematology.
Persistent Identifierhttp://hdl.handle.net/10722/163440
ISSN
2015 Impact Factor: 11.841
2015 SCImago Journal Rankings: 6.395
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_US
dc.contributor.authorKumana, CRen_US
dc.contributor.authorLee, HKKen_US
dc.contributor.authorLin, SYen_US
dc.contributor.authorLiu, Hen_US
dc.contributor.authorYeung, DYMen_US
dc.contributor.authorLau, JSMen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:31:23Z-
dc.date.available2012-09-05T05:31:23Z-
dc.date.issued2011en_US
dc.identifier.citationBlood, 2011, v. 118 n. 25, p. 6535-6543en_US
dc.identifier.issn0006-4971en_US
dc.identifier.urihttp://hdl.handle.net/10722/163440-
dc.description.abstractSeventy-six patients with acute promyelocytic leukemia (APL) in first complete remission after induction and consolidation by daunorubicin and cytosine arabinoside received oral arsenic trioxide (As 2O 3)-based maintenance. Three regimens were used: oral As 2O 3 (10 mg/day, regimen A, n ∇ 20), oral As 2O 3 plus all-trans retinoic acid (ATRA, 45 mg/m 2 per day, regimen AA, n ∇ 19), and oral As 2O 3plus ATRA plus ascorbic acid (1000 mg/day, regimen AAA, n ∇ 37), each given for 2 weeks every 2 months for 2 years. Patients receiving A, AA, and AAA maintenance did not differ significantly in clinicopathologic features and risk factors. Headache, dyspepsia, reversible liver function derangement, and herpes zoster reactivation were adverse effects observed during maintenance. QTc prolongation and arrhythmias were not encountered. At a median follow-up of 24 months (range, 1-115 months), there were 8 relapses. The 3-year leukemia-free-survival, event-free-survival, and overall-survival were 87.7%, 83.7%, and 90.6%, respectively. Adverse prognostic factors included male gender for leukemia-free-survival, and unrelated cancers for overall survival. Age, presentation WBC count and platelet count, and the type of oral As 2O 3 maintenance regimens had no impact on survivals. Prolonged oral As 2O 3 maintenance was feasible and safe and resulted in favorable outcomes when used with a simple induction and consolidation regimen compared with other protocols composed of multiple chemotherapeutic agents. © 2011 by The American Society of Hematology.en_US
dc.languageengen_US
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/en_US
dc.relation.ispartofBlooden_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshArsenicals - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshAscorbic Acid - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshCytarabine - Administration & Dosageen_US
dc.subject.meshDaunorubicin - Administration & Dosageen_US
dc.subject.meshDisease-Free Survivalen_US
dc.subject.meshDyspepsia - Chemically Induceden_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHeadache - Chemically Induceden_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Promyelocytic, Acute - Drug Therapy - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOxides - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshTretinoin - Administration & Dosage - Adverse Effectsen_US
dc.titleOral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: A 10-year follow-up studyen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1182/blood-2011-05-354530en_US
dc.identifier.pmid21998212-
dc.identifier.scopuseid_2-s2.0-84055213176en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84055213176&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume118en_US
dc.identifier.issue25en_US
dc.identifier.spage6535en_US
dc.identifier.epage6543en_US
dc.identifier.isiWOS:000298157600016-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridKumana, CR=7005112381en_US
dc.identifier.scopusauthoridLee, HKK=54787736300en_US
dc.identifier.scopusauthoridLin, SY=54788009500en_US
dc.identifier.scopusauthoridLiu, H=54788152900en_US
dc.identifier.scopusauthoridYeung, DYM=25722430700en_US
dc.identifier.scopusauthoridLau, JSM=36903981300en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.citeulike9913599-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats